Last reviewed · How we verify
Pegasys (PEGINTERFERON ALFA-2A)
Pegasys (PEGINTERFERON ALFA-2A) is a medication developed by Hoffman-La Roche, targeting the interferon alpha/beta receptor. It belongs to the interferon alpha class and is used to treat chronic hepatitis C and chronic type B viral hepatitis. Pegasys is a small molecule modality, FDA-approved in 2002, and is currently owned by Hoffman-La Roche. The medication works by modulating the immune system to fight viral infections. Its commercial status and key safety considerations are not specified in the provided facts.
At a glance
| Generic name | PEGINTERFERON ALFA-2A |
|---|---|
| Sponsor | Hoffman-La Roche |
| Target | Interferon alpha/beta receptor |
| Modality | Recombinant protein |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
- Chronic hepatitis C
- Chronic type B viral hepatitis
Common side effects
- Fatigue
- Pyrexia
- Myalgia
- Headache
- Injection site reaction
- Hypothyroidism
- Nausea/Vomiting
- Diarrhea
- Abdominal pain
- Dry mouth
- Dyspepsia
- Lymphopenia
Key clinical trials
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B (PHASE2)
- Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort (NA)
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma (PHASE1, PHASE2)
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C (PHASE3)
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegasys CI brief — competitive landscape report
- Pegasys updates RSS · CI watch RSS